Telisotuzumab Adizutecan — Drug Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

6 Recruiting

2 Completed trials

1 Sponsors

13 Countries

Phase III

Phase II/III

Phase II

Phase I/II

Phase III: 1 Phase II/III: 2 Phase II: 5 Phase I/II: 1

Indications tested

Non-small cell lung cancer 3 Colorectal cancer 2 Non-small cell lung cancer metastatic 1 MET gene amplification 1 Non-small cell lung cancer stage IV 1 Colorectal cancer metastatic 1 Non-small cell lung cancer stage IIIB 1

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 9

All trials

9 total

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older with Locally Advanced or Metastatic… Pending

2024-518871-74-00 Phase II 3 countries AbbVie Deutschland GmbH & Co. KG
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad… Recruiting

2025-521124-29-00 Phase II/III 9 countries AbbVie Deutschland GmbH & Co. KG
A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Fluorouracil, … Recruiting

2024-513008-32-00 Phase II 3 countries AbbVie Deutschland GmbH & Co. KG
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutec… Recruiting

2024-518015-19-00 Phase II 4 countries AbbVie Deutschland GmbH & Co. KG
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as Firs… Recruiting

2024-518586-10-00 Phase II/III 4 countries AbbVie Deutschland GmbH & Co. KG
A Study to Assess the Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Part… Recruiting

2024-512981-33-00 Phase II 6 countries AbbVie Deutschland GmbH & Co. KG
Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting

2024-514465-18-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 W… Ended

2023-505110-14-00 Phase II 3 countries AbbVie Deutschland GmbH & Co. KG
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONS… Ended

2024-512804-20-00 Phase III 6 countries AbbVie Deutschland GmbH & Co. KG

Showing 1–9 of 9 trials

← All drugs A–Z